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Diagnosis and management of 
hereditary haemochromatosis
M A van Bokhoven,1 C Th B M van Deursen,2 D W Swinkels3
Hereditary haemochromatosis is an autosomal recessive 
genetic disease in which increased intestinal absorption 
of iron causes accumulation in tissues, primarily the 
liver, sometimes leading to organ damage. Liver depos-
its may result in cirrhosis and even death. A systematic 
review has shown that about 0.4% of people of north-
ern European descent have the genetic mutation that 
increases the risk of developing haemochromatosis,1 but 
the clinical penetrance of the mutation is much lower 
than the genetic prevalence. Symptoms and signs are ini-
tially non-specific, so the disease is often diagnosed at 
a late stage when substantial organ damage has already 
occurred. The challenge is to avoid both overdiagnosis 
and underdiagnosis. Since the discovery of the genetic 
mutation, new knowledge has come to light on the patho-
physiology and course of the disease. This has led to new 
recommendations on diagnosis and treatment. In addi-
tion, new treatments are under evaluation. We review 
evidence from experimental and observational studies, 
systematic reviews, and guidelines to summarise for 
the general reader the clinical presentation, diagnosis, 
including early screening options, and management of 
hereditary haemochromatosis.
What is hereditary haemochromatosis?
“Hereditary haemochromatosis” is a heterogeneous 
group of disorders (box) related to deficiency of the iron 
regulatory hormone hepcidin (fig 1).2 Organs that may 
be affected by iron deposits include the liver, pancreas, 
joints, heart, skin, and gonads. Hereditary haemochro-
matosis must be distinguished from secondary forms 
of iron overload, such as those caused by repeated red 
blood cell transfusions or anaemia owing to ineffective 
erythropoiesis (fig 2). Although all lead to raised serum 
iron parameters, they are treated differently. Recent con-
sensus from the European Association for the Study of 
the Liver (EASL) defines hereditary haemochromatosis 
as “C282Y homozygosity and increased body iron stores 
with or without clinical symptoms.”1
A meta-analysis of 2802 people of European ances-
try who had clinical iron overload found that 81% were 
homozygous for the C282Y mutation in the HFE gene on 
the short arm of chromosome 6. A smaller proportion (5%) 
were compound heterozygous for the C282Y/H63D muta-
tions.1 Several other mutations in the HFE gene have been 
described, but these are rare.3 Here, we focus on C282Y 
homozygous haemochromatosis with increased body iron 
stores, which we refer to as haemochromatosis.
A systematic review of longitudinal prognostic studies 
found that 38-76% of homozygous people develop raised 
iron parameters, such as ferritin and transferrin satura-
tion in the blood (biochemical penetrance).4 However, 
clinical penetrance is lower—2-38% in men and 1-10% 
in women.5  6 The lower clinical penetrance in women is 
thought to result from iron loss through menstrual bleed-
ing and childbirth, although evidence is lacking. Genetic 
polymorphisms, antioxidant activity, inflammation, and 
environmental factors—such as alcohol misuse, steatosis, 
and coexisting viral infections—also seem to modify the 
risk of developing clinically overt disease.7  8
What are the presenting symptoms and signs?
Diabetes, bronzing of the skin, hepatomegaly, and 
arthropathy, especially of the second and third meta-
carpophalangeal joints, are typical presenting features. 
However, these are symptoms of advanced disease, and 
symptoms in early disease are non-specific. Case reports 
and observational studies have identified a wide range 
of other symptoms such as fatigue, arthropathy in other 
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recent literature seems to be of better quality.
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joints, non-specific abdominal problems, erectile dysfunc-
tion, and cardiac problems.9  10 All symptoms are thought 
to be caused by iron deposition in organs, although evi-
dence on the relation between symptoms and the extent of 
iron overload is limited.1  6  11- 13 No studies have looked at 
the predictive value of combinations of symptoms. Thus, 
it is difficult to identify patients with haemochromatosis 
from their symptoms and signs, especially for generalists, 
who usually see patients with early, non-specific symp-
toms and signs rather than advanced disease.
How can haemochromatosis be distinguished from 
other diseases?
To treat patients correctly, clinicians need to distinguish 
haemochromatosis from other diseases that result in iron 
overload, from diseases that lead to high serum ferritin 
without iron overload, and from diseases that present in 
a similar way, particularly with liver dysfunction. The dif-
ferential diagnoses are listed in the box.
The first tests to do in patients with suspected iron 
overload are measurement of iron and transferrin (which 
enables transferrin saturation to be calculated) and serum 
ferritin (fig 2).1  5  9  14 HFE genetic testing is needed only 
in those with increased transferrin saturation and after 
exclusion of common causes of hyperferritinaemia: 
inflammation (check C reactive protein), chronic alcohol 
consumption, liver cell necrosis (alanine aminotrans-
ferase), metabolic syndrome (blood pressure, body mass 
index, triglycerides, and glucose), anaemia (haemo-
globin, mean cellular volume, and ethnic background) 
as recommended by international guidelines (box).1 If 
the patient is C282Y homozygous the diagnosis of HFE 
haemochromatosis can be established. In the absence of 
these mutations, perform magnetic resonance imaging 
to assess liver iron stores.15 If liver iron is high and other 
diseases with liver iron loading, especially iron loading 
anaemias, have been excluded, perform molecular analy-
sis for rare HFE mutations and mutations in the genes 
that encode haemojuvelin, hepcidin, transferrin receptor 
2, and ferroportin, according to clinical, laboratory, and 
pathological features.16
People who present with symptoms of haemochromato-
sis and who are C282Y homozygous typically have higher 
than normal transferrin saturation and ferritin as a result of 
disrupted iron homoeostasis. The concentration of serum 
ferritin depends on the amount of iron stored in the body. 
Fig 1 | Role of hepcidin in the pathophysiology of hereditary haemochromatosis. The 
largest flux of iron involves the recycling of iron from senescent erythrocytes out of 
macrophages for incorporation into erythroid precursors (all values are approximate). Liver 
and reticuloendothelial macrophages function as major iron stores. Only 1-2 mg of iron 
is absorbed and lost every day. Importantly, the total amount of iron in the body can be 
regulated only by absorption, while iron loss occurs only passively from sloughing of skin 
and mucosal cells and from blood loss. Defects in genes encoding proteins that regulate 
synthesis of the iron regulatory hormone hepcidin in hepatocytes result in a decrease of 
serum hepcidin concentrations. Hepcidin controls the plasma iron concentration by inhibiting 
iron export by ferroportin from duodenal enterocytes and reticuloendothelial macrophages. 
A decrease in hepcidin production results in raised plasma iron values and accumulation of 
iron in the body 
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With high iron load ferritin is usually high, and this may 
correlate with the development of signs and symptoms of 
iron overload.12
Transferrin saturation
Transferrin saturation is the proportion of the iron trans-
port protein transferrin that is saturated with iron; it is cal-
culated as follows: ((serum iron (μmol/L):25)/transferrin 
(g/L))×100%. In haemochromatosis, transferrin saturation 
is generally increased throughout the day, and a non-
fasting measurement will detect high values. Transferrin 
saturation is raised as a result of innately low hepcidin, 
which leads to increased iron uptake from the intestine 
and iron release by reticuloendothelial macrophages.17 
Transferrin saturation can also be high in people with iron 
loading anaemias, those taking iron tablets or multivita-
mins containing iron, patients with hepatitis, and people 
who misuse alcohol.
The reference range for transferrin saturation is 15-45%; 
expert consensus considers 45% to be the upper limit of 
normal in a non-fasting situation,1  9 although higher cut-
off values are sometimes recommended for population 
screening programmes.18
Serum ferritin
Serum ferritin is an indirect measure of body iron stores 
and is increased in patients with iron overload, viral 
infections, other inflammatory conditions, the metabolic 
Fig 2 | Diagnostic flowchart for patients with suspected haemochromatosis. *The reference range for transferrin saturation 
is 15-45%. †The ferritin range differs between laboratories and methodologies used. Usual upper reference values are 
about 300 µg/L and 200 µg/L for men and women, respectively. ‡If rare HFE mutations are present the diagnosis is HFE 
haemochromatosis; if mutations in the genes for the transferrin receptor 2, haemojuvelin, hepcidin, or ferroportin are detected 
the diagnosis is non-HFE haemochromatosis; in the presence of any of these mutations, treat patients the same as those with HFE 
haemochromatosis regarding phlebotomy, screening relatives, and periodic screening of the liver in those with liver cirrhosis. 
§Iron overload in the liver may also result from end stage cirrhosis; in exceptional cases, further diagnostic considerations then 
depend on cellular and nodular distributions of iron and associated findings such as fibrosis on liver biopsy. ¶In the absence of 
cirrhosis, regular screening by echography or magnetic resonance imaging is not indicated
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PATIENT’S STORY
The first symptom was painful swelling of my hand, for 
which I was referred to a rheumatologist. He suspected 
haemochromatosis because of my bronzed skin and 
ordered the relevant tests. In retrospect, this explains my 
“fatty liver” that had been diagnosed by a screening test 
at work. After the diagnosis I was treated with frequent 
phlebotomies, which made me so tired that I could no 
longer work full time. Currently, my worst problem is pain 
in my hips and finger. None of the available painkillers is 
effective. Furthermore, I have fatigue, which means that I 
have to plan my activities carefully. Thirdly, I have erectile 
dysfunction. Fortunately, my wife and I have found other 
ways to reach intimacy. My children and my sisters 
have been screened for the mutation and had their iron 
parameters measured. Luckily, none of them are affected. 
I used to undergo phlebotomies biweekly. However, 
since I have been given esomeprazol my iron parameters 
remain stable and I no longer need to be bled. I worry 
about symptoms that might arise in the future, such as 
problems with my heart.
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ONGOING RESEARCH
• New chelators, hepcidin agonists, proton pump inhibitors, and calcium antagonists are 
under evaluation. Clinical trials are needed to assess their clinical value 
• The predictive value of various combinations of symptoms for the presence of 
haemochromatosis
• The optimal screening approach
• Parameters that could help determine the optimum frequency of phlebotomy and the 
quantity of blood taken at each session, including the optimum target value of serum ferritin
• Non-invasive alternatives to liver biopsy as an indicator of liver damage
• Greater understanding of how the synthesis of hepcidin is regulated in the liver may 
provide insight into the reasons for low clinical penetrance and provide markers that could 
help predict penetrance in C282Y homozygotes
• International and national evidence based clinical practice guidelines must be developed 
and implemented because differences between centres cause anxiety among patients
 syndrome, cancer, and chronic liver disease (for example, 
as a result of alcohol misuse); it is also raised in patients 
on dialysis and as a result of drug toxicity. Many immuno-
chemical methods are available to measure serum ferritin. 
We recommend using local reference values because the 
inter-laboratory coefficient of variance of serum ferritin 
concentrations is high, 6-13% (source: Foundation of 
quality control of medical laboratory diagnostics (SKML) 
data on interlaboratory variance of serum ferritin from 
about 270 Dutch laboratories in 2009). Upper reference 
values are about 300 µg/L and 200 µg/L for men and 
women, respectively.
Genetic testing
When symptoms and serum iron parameters suggest 
haemochromatosis genetic testing is indicated. A sys-
tematic review found sensitivity and specificity of C282Y 
homozygosity to be above 90% and almost 100%, respec-
tively, for the presence of an iron overload phenotype in 
white northern Europeans.19
A recent prospective population based cohort study 
showed that documented iron overload disease is rare 
among C282Y/H63D compound heterozygotes.20 An 
advantage of genetic testing in patients with signs of 
increased iron stores is the certainty of the diagnosis, and 
this has important implications for treatment and counsel-
ling of first degree relatives. If a symptomatic patient is a 
C282Y homozygote, screening of first degree relatives for 
the presence of the genotype may be indicated.21
Magnetic resonance imaging and liver biopsy
If the diagnosis is still unsure after blood analysis and test-
ing for the C282Y and H63D polymorphisms of the HFE 
gene, magnetic resonance imaging might be helpful. A 
reliable, quantitative imaging technique for the detection 
of iron in the liver is available.15 If the expertise or facilities 
to offer the technique is lacking, tissue from a liver biopsy 
may be analysed to look for iron deposits. If the concentra-
tion of iron deposits is below the cut-off value, haemochro-
matosis can be excluded, but if it is above, genetic testing 
for rare haemochromatosis mutations is indicated.9
What is the prognosis for patients with 
haemochromatosis?
A meta-analysis found that C282Y homozygous patients 
with clinically ascertained haemochromatosis have an 
increased risk of developing liver disease (odds ratio 3.9, 
99% confidence interval 1.9 to 8.1) and hepatocellular 
carcinoma (11, 3.7 to 34).11 A population screening sur-
vey of 65 238 people showed that the absolute risk of liver 
damage is about 5% in homozygous men and less than 1% 
in women.22 Patients with either of these complications 
have a reduced life expectancy. However, observational 
studies of patients who received adequate and timely treat-
ment, of people identified by population screening, and 
of previously undiagnosed family members of patients 
with haemochromatosis show that overall mortality is not 
higher than in the general  population.5  23- 25
Is screening indicated?
Population screening
The relatively high prevalence of the C282Y homozygous 
genotype in European populations led several authors 
to recommend population screening.26  27 However, the 
low clinical penetrance means that many people would 
be incorrectly diagnosed with haemochromatosis when 
not clinically unwell, which could be harmful and could 
lead to problems with obtaining medical insurance. A 
systematic review therefore concluded that population 
TIPS FOR NON-SPECIALISTS
• Haemochromatosis usually starts with non-specific symptoms and signs. Although 
evidence is lacking, consider testing for the disease in patients who have had unexplained 
symptoms for several months
• First test for serum ferritin, serum iron, and transferrin, then calculate the transferrin 
saturation value. If serum ferritin and transferrin saturation are both high, refer the patient 
to a specialist in haemochromatosis (usually a gastroenterologist)
• Repeated phlebotomy is the cornerstone of treatment, although new treatments are under 
development
• Population screening is not indicated. Screening of first degree relatives with symptomatic 
haemochromatosis is indicated
• If treated adequately, patients with symptomatic haemochromatosis have a normal life 
expectancy
ADDITIONAL EDUCATIONAL RESOURCES
Resources for healthcare professionals
European Iron Club (www.euro-iron.org)—European organisation for professionals 
interested in iron metabolism 
International BioIron Society (www.bioiron.org)—International organisation for 
professionals interested in iron metabolism 
Lee PL, Beutler E. Regulation of hepcidin and iron-overload disease. Annu Rev Pathol Mech 
Dis 2009;4:489-515
Weiss G. Genetic mechanisms and modifying factors in hereditary hemochromatosis. Nat 
Rev Gastroenterol Hepatol 2010;7:50-8. 
American Association for the Study of Liver Diseases. Practice guidelines. www.aasld.org/
practiceguidelines/Pages/PracticeGuidelinesAlpha.aspx 
European Association for the Study of the Liver. EASL clinical practice guidelines for HFE 
hemochromatosis. J Hepatol 2010;53:3-22
Resources for patients
The European Federation of Associations of Patients with Haemochromatosis (www.
european-haemochromatosis.eu)—Provides links to patient organisations in several 
countries
American Hemochromatosis Society (www.americanhs.org)—Provides education and 
support for patients   
Up-to-Date (www.utdol.com/patients/content/topic.do?topicKey=~jO3tricadskc9/#H25)—
Overview about haemochromatosis
Haemochromatosis Society UK (www.haemochromatosis.org.uk/home.html)—Provides 
help, support, and information for those affected by haemochromatosis 
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screening is not recommended because the harms exceed 
the benefits.28
Screening those with haemochromatosis related diseases
New EASL guidelines recommend considering genetic 
testing for patients with porphyria cutanea tarda, well 
defined chondrocalcinosis, hepatocellular carcinoma, 
late onset type 1 diabetes, and those presenting with a 
combination of unexplained chronic liver disease and 
raised transferrin saturation. Although the evidence is 
limited, these diseases are associated with a higher preva-
lence of C282Y homozygosity.1
Screening people with a positive family history
Screening first degree relatives of patients diagnosed 
with haemochromatosis is another option. A modelling 
study showed that for patients with two or more children, 
the most cost effective approach is to test the patient’s 
spouse first and test the children only if the spouse is 
 heterozygous. For one child or siblings, direct testing 
for the mutation is the most cost effective strategy.21 The 
value of testing for the C282Y mutation is still unclear 
because of the unknown risk of developing biochemical or 
clinical signs of haemochromatosis even in homozygotes. 
This is even more the case when testing for C282Y/H63D 
compound heterozygosity. This is because the chance of 
finding this genotype in relatives of a C282Y homozygous 
proband is relatively high (the population frequency of 
the H63D mutation is 20%); documented iron overload 
in people with this genotype is rare20; and disease pen-
etrance in the absence of comorbid factors is low, as is 
shown in an observational study.29
However, an observational study of first degree r elatives 
of C282Y homozygous patients found that haemochroma-
tosis related symptoms are more common than in controls 
and that their level of iron overload may be predicted by 
disease severity in the index patient.25  30 Because the 
first symptoms develop during adulthood, the choice of 
whether or not to test can be postponed until children are 
grown up and can decide for th emselves.
How is hereditary haemochromatosis treated?
Phlebotomy
Haemochromatosis is usually treated with phlebotomy. 
Each 500 mL of blood contains 0.25 g of iron. The con-
centration of iron above which phlebotomy is indicated is 
not clear. A meta-analysis has shown that serum ferritin 
concentrations above 1000 µg/L may cause cirrhosis of 
the liver.11 A consensus based approach is to start treat-
ment when serum ferritin rises above local reference val-
ues (about 300 µg/L and 200 µg/L for men and women, 
respectively).1 However, not all patients with raised serum 
ferritin show further increases.31 Therefore, for patients 
with moderately raised serum ferritin a “watchful wait-
ing” approach, with phlebotomy only when their serum 
ferritin increases progressively, might be an alternative to 
regular phlebotomy.32
The optimum frequency of phlebotomy and quantity 
of blood taken are unclear, but expert consensus sug-
gests that 500 mL of blood should be taken each week 
in the depletion stage, guided most usually by serum fer-
ritin and haemoglobin values.1  9 The procedure used is 
similar to that for blood donations. If phlebotomy results 
in anaemia, or adverse consequences of hypovolaemia, 
frequency of bleeding or volumes of blood taken can be 
adjusted.
No evidence is available to help set a target value for 
serum ferritin. Some authors recommend aiming for 
50 µg/L or even lower.1 However, it might be better to aim 
for values within the normal range because these might be 
better tolerated by patients, result less often in anaemia, 
and prevent an increase in intestinal iron uptake caused 
by further lowering of hepcidin as a result of intensive 
blood letting.33 The maintenance stage is reached when 
serum ferritin drops below the target value. The optimum 
frequency of phlebotomy will depend on the patient’s 
symptoms and response to treatment, the serum ferritin 
value at diagnosis, and patient preferences.
An observational study reported that adherence to 
phlebotomy was greater than 90%.34 The main negative 
effects were problems with venous access and the time 
consuming nature of the treatment.35 Observational stud-
ies have shown that fibrosis of the liver may be reversed 
by phlebotomy. The effects on symptoms have not been 
evaluated extensively, and reviews show that treatment 
can improve some symptoms, such as fatigue and skin 
pigmentation, but not others, such as arthralgia.1  9  36 
In addition, evidence that treatment improves survival 
is limited because the low absolute risk of death from 
 cirrhosis or hepatocellular carcinoma makes it difficult to 
show an effect using observational data.23 A randomised 
clinical trial to evaluate the effect of phlebotomy would 
probably be considered unethical and would be compli-
cated because of variable penetrance.
Iron chelation
Currently, the only routinely available alternative to 
phlebotomy is iron chelation, which is more costly and 
has more side effects. In iron chelation with desferriox-
amine ferric ions are bound into ferrioxamine complex 
and eliminated from the body via the urine. Side effects 
include gastrointestinal symptoms, dizziness, visual and 
auditory impairments, muscle cramps, tachycardia, and 
thrombopenia. Experts recommend chelation with desfer-
rioxamine only when phlebotomy is contraindicated—for 
example, when venous access cannot be obtained and in 
patients with circulatory problems (such as heart failure 
or anaemia).
Therapeutic erythrocytapheresis
Therapeutic erythrocytapheresis is the removal of eryth-
rocytes only rather than whole blood that could become 
an alternative to phlebotomy. Preliminary results show 
that erythrocytapheresis leads to a fourfold reduction of 
phlebotomy sessions. More than twice as much iron can 
be removed per session and side effects are reduced.37
What can patients do to influence the disease?
Whether avoiding dietary iron reduces iron storage has 
not been investigated. Expert consensus opinion is that 
patients should avoid iron containing food supplements.1 
Patients might want to limit alcohol consumption, 
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es pecially when not yet iron depleted, because alcohol 
has a toxic effect on the liver and may also suppress hep-
cidin expression, as summarised in two reviews.1  38 How-
ever, dietary advice that is too strict may reduce quality of 
life or even reduce adherence.
How do we monitor patients with haemochromatosis?
Patients are monitored mainly to guide the timing of 
treatment and detect liver damage. Serum ferritin is the 
main parameter used because an observational study 
found that it correlates with symptoms and the risk of 
complications. A cross sectional study showed that when 
serum ferritin is less than 1000 µg/L the risk of serious 
liver damage is below 1%.39 Serum ferritin levels above 
1000 µg/L are, according to international consensus, 
an indication for liver biopsy because of the risk of cir-
rhosis.1  9 When a liver biopsy shows cirrhosis, periodic 
screening for hepatocellular carcinoma becomes man-
datory. This can be done with echography or magnetic 
resonance imaging.
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